Get the Stockscreener App
10.68
4.30%
-0.48
After Hours:
10.68
Alumis Inc stock is traded at $10.68, with a volume of 111.81K.
It is down -4.30% in the last 24 hours and down -15.91% over the past month.
Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies.
See More
Previous Close:
$11.16
Open:
$11.1
24h Volume:
111.81K
Relative Volume:
0.61
Market Cap:
$581.03M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-9.95%
1M Performance:
-15.91%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$10.46
$11.60
1-Week Range:
$10.46
$12.56
52-Week Range:
$10.37
$13.50
Alumis Inc Stock (ALMS) Company Profile
Name
Alumis Inc
Sector
Industry
Phone
650-231-6625
Address
280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Alumis Inc Stock (ALMS) Latest News
Alumis (NASDAQ:ALMS) Trading Down 4.8% - MarketBeat
Alumis reports progress in psoriasis treatment trial By Investing.com - Investing.com South Africa
Alumis reports progress in psoriasis treatment trial - Investing.com India
Alumis reports progress in psoriasis treatment trial By Investing.com - Investing.com Canada
Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study - The Manila Times
ALMSAlumis Inc. Latest Stock News & Market Updates - StockTitan
Alumis (NASDAQ:ALMS) Trading Up 4.8% - MarketBeat
(ALMS) Technical Data - Stock Traders Daily
Alumis (NASDAQ:ALMS) Shares Gap Down to $11.86 - Defense World
Alumis (NASDAQ:ALMS) Shares Gap Down to $11.86 - MarketBeat
Yu Fan Purchases New Stake in Alumis Inc. (NASDAQ:ALMS) - MarketBeat
Alumis Inc. [ALMS] Stock bought by Insider Foresite Labs, LLC for $40.0 million - Knox Daily
Taking on analysts’ expectations and winning: Alumis Inc. (ALMS) - SETE News
SR One Capital Management LP Invests $26.07 Million in Alumis Inc. (NASDAQ:ALMS) - MarketBeat
Alumis (NASDAQ:ALMS) Shares Down 2.6% - MarketBeat
Alumis (NASDAQ:ALMS) Trading 5.3% Higher - MarketBeat
Alumis (NASDAQ:ALMS) Stock Price Up 5.3% - Defense World
Alumis (NASDAQ:ALMS) Reaches New 12-Month Low at $10.37 - MarketBeat
Alumis: Recent IPO With Differentiated Data In Autoimmune Diseases (NASDAQ:ALMS) - Seeking Alpha
Vatroslav Mateljic Appointed General Manager of Takeda Canada - Quantisnow
Objective long/short (ALMS) Report - Stock Traders Daily
TPG-backed Bicara Therapeutics shares surge 46% in stellar market debut - Reuters
Alumis (NASDAQ:ALMS) Shares Up 8.6% - MarketBeat
Alumis (NASDAQ:ALMS) Stock Price Down 4.6% - MarketBeat
Psoriasis Market is anticipated to rise at a notable CAGR, estimates DelveInsight | Hangzhou Highlightll Pharmaceutical Co., Ltd, Biohaven Pharmaceuticals, Inc., SFA Therapeutics, Bristol-Myers Squibb - Barchart
Biotech IPO Hopefuls Ready Burst of Debuts After Rough Stretch - BNN Bloomberg
Alumis (NASDAQ:ALMS) Shares Gap Up to $12.20 - MarketBeat
Alumis to Participate in Upcoming September Investor Conferences - ForexTV.com
Understanding the Risks of Investing in Alumis Inc. (ALMS) - Knox Daily
Recent Insider Activity Suggests Potential Gains for Sezzle Inc. (SEZL) - Knox Daily
(ALMS) On The My Stocks Page - Stock Traders Daily
Alumis (NASDAQ:ALMS) Shares Down 4.8% - Defense World
Alumis (NASDAQ:ALMS) Shares Down 4.8% - MarketBeat
Cantor Fitzgerald Equities Analysts Lift Earnings Estimates for Alumis Inc. (NASDAQ:ALMS) - MarketBeat
Alumis Inc. (NASDAQ:ALMS) Forecasted to Earn FY2024 Earnings of ($5.67) Per Share - Defense World
Cantor Fitzgerald Reiterates Overweight Rating for Alumis (NASDAQ:ALMS) - MarketBeat
Q3 2024 EPS Estimates for Alumis Inc. Decreased by Leerink Partnrs (NASDAQ:ALMS) - MarketBeat
Alumis (NASDAQ:ALMS) Shares Gap Down to $12.54 - MarketBeat
Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements - BioSpace
Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and - The Bakersfield Californian
Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements - wallstreet:online
Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements - ForexTV.com
Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements - StockTitan
(ALMS) Trading Report - Stock Traders Daily
Q&A: Alumis Inc. Initiates Phase 3 Clinical Program for ESK-001 in Plaque Psoriasis - Dermatology Times
Checking in on Alumis Inc. (ALMS) after recent insiders movement - Knox Daily
Alumis Inc.'s Quiet Period Set To End on August 7th (NASDAQ:ALMS) - MarketBeat
Telomir Pharmaceuticals, Inc.’s Lock-Up Period Will Expire on August 7th (NASDAQ:TELO) - Defense World
BBB Foods Inc.’s Lock-Up Period Will Expire on August 7th (NYSE:TBBB) - Defense World
Alumis (NASDAQ:ALMS) Stock Price Down 5.9% - MarketBeat
Potential Competitor To BMS’s Sotyktu Bites The Dust - Scrip
Alumis Inc Stock (ALMS) Financials Data
There is no financial data for Alumis Inc (ALMS). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):